IRIDEX CORP

IRIDEX CORP (IRIX) is a publicly listed company on US equity markets.

IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

The company reports trailing twelve-month revenue of $10.30M and net loss of $524,000.

Key metrics include a return on equity of -11.1%, a debt-to-equity ratio of 4.98.

Use FINOTAUR to track IRIX's price action, review fundamentals, and stay current with company news — all in one research dashboard.